Research programme: nucleic acid therapeutics - Promosome/Unknown company

Drug Profile

Research programme: nucleic acid therapeutics - Promosome/Unknown company

Latest Information Update: 16 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Promosome; Unknown
  • Developer Promosome
  • Class DNA vaccines; Gene therapies; Nucleic acids, nucleotides, and nucleosides; RNA vaccines
  • Mechanism of Action RNA interference; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 07 Sep 2016 mRNA engineering technologies developed at the Scripps Research Institute licensed to Promosome, world-wide, before September 2016 (Promosome website, September 2016)
  • 07 Sep 2016 Promosome and an Unknwon company enter into a collaboration for the development of nucleic acid therapeutics based on Promosome's mRNA engineering tools
  • 07 Sep 2016 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top